Valeriy Ivanov, Tetiana Onyshchuk


The aim of the research was to describe the clinical charachters of male and female patients with stage II arterial hypertension (AH) of young and middle age with different gradations of galectin-3 plasma levels according to multiple linear stepwise regression analysis.

Materials and methods: 160 patients with AH of different sex (male and female) and age (young (18–44 years), middle (45–60 years)) were examined (clinical, laboratory and instrumental). Multiple linear regression was used to determine the clinical presentation of patients with AH at different levels of the neurohormone (StatSoft's Statistica MultipleRegression v. 10.0 module). which were divided into groups that vi told for the entirely different patient characteristics. multiple linear regression was performed for each indicator separately and the results have been shaped in the form of regression equations.

Results. Patients with young and middle-aged AH have been found to be relatively high (RH) levels of galectin-3 associated with: the presence of a complex of metabolic risk factors – obesity and dyslipidemia; in combination with multiple features of structural and functional changes in the cardiovascular system, such as the presence of concentric left ventricular (LV) hypertrophy in combination with myocardial relaxation disorders (Е/e' aver>7.2) and signs of hemodynamic overload of the left atrium (LA) (LA volume index (LAVi)>34 ml/m2); the presence of valve dysfunctions in the form of mitral (1–2 degree) and aortic regurgitation (1 stage); the presence of structural remodeling of the carotid arteries (intima-media thickness (IMT)>0.91 mm). Plasma abdominal obesity was the most informative marker of RH galectin-3 in plasma, IMT>0.91 mm and LAVi>34 ml/m2.

Conclusions. The association of plasma galectin-3 levels with various clinical and instrumental indicators indicates a certain effect of the neurohormone on the course of AH in young and middle-aged male and female patients. Of indisputable interest is the determination of the features of the course of AH and the clinical profile of patients at different gradations (relatively low (RL), relatively moderate (RM) and relatively high (RH)) galectin-3 plasma level.


hypertension; galectin-3; aldosterone; obesity; dyslipidemia

Full Text:



Onyshсhuk, T. P. (2018). Determination of plasma level of galectin-3 in young and middle-aged patients with hypertonic disease of stage II. Bukovinian Medical Herald, 22 (4 (88)), 98–106. doi:

Onyshchuk, T. P., Ivanov, V. P. (2019). Characteristics of indices of the carotid arteries structural condition in patients with hypertension depending on galectin-3 and aldosterone levels. Art of medicine, 3 (11), 28–32.

Ruzhanska, V. O., Sivak, V. G., Zhebel, V. М., Pashkova, Yu. P. (2017). Galactin-3 as biomarker of chronic heart failure in patients with essential hypertension of men. Reports of Vinnytsia National Medical University, 21 (2), 563–569.

Pugliese, G., Iacobini, C., Pesce, C. M., Menini, S. (2014). Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology, 25 (2), 136–150. doi:

De Boer, R. A., van Veldhuisen, D. J., Gansevoort, R. T., Muller Kobold, A. C., van Gilst, W. H., Hillege, H. L. et. al. (2011). The fibrosis marker galectin-3 and outcome in the general population. Journal of Internal Medicine, 272 (1), 55–64. doi:

Tseluyko, V. І., Zhadan, A. V., Zedginidze, E. (2015). Galectin-3 and reverse cardiac remodeling after surgical treatment of mitral insufficiency. Ukrainskyi kardiolohichnyi zhurnal, 6, 79–82.

Ahmad, T., Michael Felker, G. (2012). Galectin‐3 in Heart Failure: More Answers or More Questions? Journal of the American Heart Association, 1 (5). doi:

Calvier, L., Miana, M., Reboul, P., Cachofeiro, V., Martinez-Martinez, E., de Boer, R. A. et. al. (2013). Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 33 (1), 67–75. doi:

Boulogne, M., Sadoune, M., Launay, J., Baudet, M., Cohen-Solal, A., Logeart, D. (2017). Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. International Journal of Cardiology, 226, 53–59. doi:

Billebeau, G., Vodovar, N., Sadoune, M., Launay, J.-M., Beauvais, F., Cohen-Solal, A. (2017). Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure. European Journal of Preventive Cardiology, 24 (11), 1127–1135. doi:

Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M. et. al. (2013). ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension, 31 (7), 1281–1357. doi:

Unifikovanyi klinichnyi protokol pervynnoi, ekstrenoi ta vtorynnoi (spetsializovanoi) medychnoi dopomohy. Arterialna hipertenziia (2012). Nakaz Ministerstva okhorony zdorovia No. 384. 24.05.2012. Kyiv, 72.

Gurses, K. M., Yalcin, M. U., Kocyigit, D., Canpinar, H., Evranos, B., Yorgun, H. et. al. (2015). Effects of Persistent Atrial Fibrillation on Serum Galectin-3 Levels. The American Journal of Cardiology, 115 (5), 647–651. doi:

Clementy, N., Piver, E., Benhenda, N., Bernard, A., Pierre, B., Siméon, E. et. al. (2014). Galectin-3 in patients undergoing ablation of atrial fibrillation. IJC Metabolic & Endocrine, 5, 56–60. doi:



  • There are currently no refbacks.

Copyright (c) 2019 Valeriy Ivanov, Tetiana Onyshchuk

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2504-5679 (Online), ISSN 2504-5660 (Print)